{ }
001122334455554433221100
001122334455554433221100

Swiss stock market rises as UBS faces pressure from potential capital requirements

The Swiss stock market continued its upward trend, with the SMI rising 0.5% to 12,420 points, fueled by optimism over potential trade deals and peace talks regarding Ukraine. Sika led the blue-chip gains with a 1.9% increase, while UBS faced pressure amid concerns over stricter capital requirements. VAT Group's shares fell 2.6% as it revised its sales growth outlook for 2025-2029.

ubs warns relocation could harm long term growth of swiss economy

UBS warns that rising protectionism may lead Swiss companies to relocate production abroad, potentially undermining the country's long-term growth. A survey reveals that half of larger firms considering new outlets are focused on the U.S., with significant investments announced by Novartis and Roche. Economists predict a slowdown in Swiss growth, forecasting a 1% GDP increase for 2025, down from 1.5%.

Swiss companies consider relocation amid rising tariffs and protectionism concerns

Swiss companies are increasingly considering relocation due to rising protectionism and tariffs, with half of exporters exploring new markets. A significant 50% of firms focused on the U.S. view relocation as likely, while only 25% of SMEs are contemplating such moves. UBS warns that these trends could hinder Switzerland's long-term economic growth, which is already projected to slow to 1% in 2025.

Swiss executives benefit from undervalued share portfolios boosting their earnings

Swiss CEOs and board members, including UBS's Sergio Ermotti and Holcim's Jan Jenisch, often receive significantly higher compensation than reported due to undervalued share portfolios. For instance, Ermotti's 2023 earnings could have reached CHF 18.4 million if shares were valued accurately, while Jenisch's total compensation included CHF 48 million, largely from stock options. Roche's Severin Schwan and Nestlé's Mark Schneider also illustrate this trend, with substantial portions of their pay linked to undervalued shares.

swiss ceos benefit from undervalued share packages boosting their bonuses

Swiss CEOs, including UBS's Sergio Ermotti and Holcim's Jan Jenisch, are criticized for receiving substantial hidden bonuses due to undervalued share packages. Ethos Foundation highlights that these packages are often valued significantly below market rates, inflating actual remuneration over time. For instance, Ermotti's compensation could have reached CHF 18.4 million if shares were valued correctly, while Roche's Severin Schwan also benefits from similar undervaluation practices.

ubs rates roche holdings ag as buy amid investment considerations

UBS has rated Roche Holdings AG as 'Buy', indicating a positive outlook on the stock. However, the information provided is for informational purposes only and does not constitute a recommendation to buy or sell. Investors are cautioned about the risks involved in purchasing securities, which may lead to total capital loss.

Roche Holdings AG maintains positive outlook in healthcare research and diagnostics

Roche Holding AG operates in healthcare research, divided into Pharmaceuticals and Diagnostics. The Pharmaceuticals Division includes Roche Pharmaceuticals and Chugai, focusing on drug development for oncology, immunology, and more, with notable products like Avastin and MabThera. The Diagnostics Division offers advanced tools for cell analysis and gene expression.

ubs rates roche holdings ag as buy amid investment considerations

UBS has rated Roche Holdings AG as a 'Buy'. The information provided is for informational purposes only and does not constitute a recommendation to buy or sell securities. Investing in securities carries risks, including the potential loss of the entire capital invested.

Roche Holdings AG Receives Positive Outlook from UBS Amid Diverse Healthcare Innovations

Roche Holding AG operates in healthcare research, divided into Pharmaceuticals and Diagnostics. The Pharmaceuticals Division includes Roche Pharmaceuticals and Chugai, focusing on drug development for oncology, immunology, infectious diseases, ophthalmology, and neuroscience. Its Diagnostics Division encompasses Diabetes Care, Molecular Diagnostics, Professional Diagnostics, and Tissue Diagnostics, offering products for researchers in cell analysis and genome sequencing.

Swiss stock market edges up as Oerlikon and Basilea report strong results

The Swiss stock market closed slightly higher, with the SMI rising 0.15% to 12,893.98 points, buoyed by gains in cyclical and financial stocks. Notable performers included OC Oerlikon (+8.7%) and Basilea (+8.3%), while Lonza (-2.7%) and Siegfried (-6.3%) faced declines due to conservative outlooks. Encouraging economic signals from Germany and the USA contributed to a positive market sentiment.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.